drugset
drugset / Trial / NCT03264157

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

NCT03264157 ↗

Phase 2/3 Completed 162 enrolled Bio Products Laboratory
RandomizedParallel-groupDouble-blindTreatment

Summary

A prospective, randomized, blinded, parallel-group, non-inferiority, phase II/III study of the safety and effectiveness of simulated post-exposure prophylaxis with BPL HRIG with co-administration of active rabies vaccine in healthy subjects.

Timeline

Start
2017-12-08
Primary completion
2018-03-02
Completion
2018-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject HRIG Unknown 20 iu/kg Intramuscular
Comparator HyperRAB Unknown 20 iu/kg Intramuscular
Background Rabies vaccine Vaccine 1 ml Intramuscular

Indications

No indication recorded.